Medical - Healthcare Information Services
Build Your Comparison
Side-by-side financial analysisStock Comparison
DOCS vs VEEV vs KO vs PEP vs CRM
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Information Services
Beverages - Non-Alcoholic
Beverages - Non-Alcoholic
Software - Application
DOCS vs VEEV vs KO vs PEP vs CRM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Healthcare Information Services | Beverages - Non-Alcoholic | Beverages - Non-Alcoholic | Software - Application |
| Market Cap | $3.75B | $25.92B | $355.61B | $197.17B | $135.86B |
| Revenue (TTM) | $645M | $3.32B | $49.28B | $93.92B | $42.83B |
| Net Income (TTM) | $196M | $942M | $13.70B | $8.24B | $8.02B |
| Gross Margin | 89.1% | 75.0% | 61.7% | 54.1% | 77.6% |
| Operating Margin | 33.3% | 28.8% | 29.3% | 12.2% | 21.9% |
| Forward P/E | 14.0x | 17.6x | 25.3x | 16.7x | 14.1x |
| Total Debt | $10M | $96M | $45.49B | $49.90B | $17.18B |
| Cash & Equiv. | $219M | $1.42B | $10.27B | $9.16B | $7.33B |
DOCS vs VEEV vs KO vs PEP vs CRM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 21 | Jun 26 | Return |
|---|---|---|---|
| Doximity, Inc. (DOCS) | 100 | 34.4 | -65.6% |
| Veeva Systems Inc. (VEEV) | 100 | 51.3 | -48.7% |
| The Coca-Cola Compa… (KO) | 100 | 152.7 | +52.7% |
| PepsiCo, Inc. (PEP) | 100 | 97.4 | -2.6% |
| Salesforce, Inc. (CRM) | 100 | 67.9 | -32.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DOCS vs VEEV vs KO vs PEP vs CRM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DOCS carries the broadest edge in this set and is the clearest fit for valuation efficiency.
- PEG 0.27 vs PEP's 5.11
- Lower P/E (14.0x vs 16.7x), PEG 0.27 vs 5.11
- 30.4% margin vs PEP's 8.8%
- 16.5% ROA vs PEP's 7.7%, ROIC 19.8% vs 14.9%
VEEV is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 16.3%, EPS growth 25.9%, 3Y rev CAGR 14.0%
- Lower volatility, beta 0.69, Low D/E 1.3%, current ratio 4.89x
- 16.3% revenue growth vs KO's 1.9%
KO ranks third and is worth considering specifically for long-term compounding.
- 121.1% 10Y total return vs VEEV's 367.2%
- +17.2% vs DOCS's -64.8%
PEP is the clearest fit if your priority is income & stability.
- Dividend streak 54 yrs, beta -0.11, yield 3.9%
- 3.9% yield, 54-year raise streak, vs KO's 2.5%, (2 stocks pay no dividend)
CRM is the clearest fit if your priority is defensive.
- Beta 0.64, yield 1.0%, current ratio 0.76x
- Beta 0.64 vs DOCS's 0.75
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.3% revenue growth vs KO's 1.9% | |
| Value | Lower P/E (14.0x vs 16.7x), PEG 0.27 vs 5.11 | |
| Quality / Margins | 30.4% margin vs PEP's 8.8% | |
| Stability / Safety | Beta 0.64 vs DOCS's 0.75 | |
| Dividends | 3.9% yield, 54-year raise streak, vs KO's 2.5%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +17.2% vs DOCS's -64.8% | |
| Efficiency (ROA) | 16.5% ROA vs PEP's 7.7%, ROIC 19.8% vs 14.9% |
DOCS vs VEEV vs KO vs PEP vs CRM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
DOCS vs VEEV vs KO vs PEP vs CRM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
DOCS leads in 2 of 6 categories
KO leads 2 • VEEV leads 0 • PEP leads 0 • CRM leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
DOCS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
PEP is the larger business by revenue, generating $93.9B annually — 145.7x DOCS's $645M. DOCS is the more profitable business, keeping 30.4% of every revenue dollar as net income compared to PEP's 8.8%. On growth, VEEV holds the edge at +16.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $645M | $3.3B | $49.3B | $93.9B | $42.8B |
| EBITDAEarnings before interest/tax | $227M | $1.1B | $15.5B | $14.3B | $12.2B |
| Net IncomeAfter-tax profit | $196M | $942M | $13.7B | $8.2B | $8.0B |
| Free Cash FlowCash after capex | $215M | $518M | $12.6B | $7.7B | $14.7B |
| Gross MarginGross profit ÷ Revenue | +89.1% | +75.0% | +61.7% | +54.1% | +77.6% |
| Operating MarginEBIT ÷ Revenue | +33.3% | +28.8% | +29.3% | +12.2% | +21.9% |
| Net MarginNet income ÷ Revenue | +30.4% | +28.4% | +27.8% | +8.8% | +18.7% |
| FCF MarginFCF ÷ Revenue | +33.3% | +15.6% | +25.5% | +8.2% | +34.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.1% | +16.3% | +12.1% | +5.6% | +13.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -67.7% | +14.6% | +18.2% | +66.7% | +52.2% |
Valuation Metrics
Evenly matched — DOCS and CRM each lead in 3 of 7 comparable metrics.
Valuation Metrics
At 20.4x trailing earnings, DOCS trades at a 30% valuation discount to VEEV's 29.3x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.39x vs PEP's 7.37x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $3.7B | $25.9B | $355.6B | $197.2B | $135.9B |
| Enterprise ValueMkt cap + debt − cash | $3.5B | $24.6B | $390.8B | $237.9B | $145.7B |
| Trailing P/EPrice ÷ TTM EPS | 20.45x | 29.33x | 27.18x | 24.05x | 21.27x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.99x | 17.61x | 25.27x | 16.68x | 14.09x |
| PEG RatioP/E ÷ EPS growth rate | 0.39x | 1.61x | 2.43x | 7.37x | 1.74x |
| EV / EBITDAEnterprise value multiple | 16.47x | 20.59x | 26.39x | 16.63x | 11.61x |
| Price / SalesMarket cap ÷ Revenue | 5.81x | 8.11x | 7.42x | 2.10x | 3.27x |
| Price / BookPrice ÷ Book value/share | 4.20x | 3.69x | 10.40x | 9.63x | 2.68x |
| Price / FCFMarket cap ÷ FCF | — | 18.70x | 67.15x | 25.70x | 9.43x |
Profitability & Efficiency
DOCS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $13 for VEEV. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to PEP's 2.43x. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs PEP's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +19.4% | +13.4% | +41.1% | +40.1% | +14.9% |
| ROA (TTM)Return on assets | +16.5% | +11.0% | +13.1% | +7.7% | +7.8% |
| ROICReturn on invested capital | +19.8% | +12.9% | +15.8% | +14.9% | +10.1% |
| ROCEReturn on capital employed | +20.7% | +13.8% | +17.3% | +16.1% | +11.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 7 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.01x | 0.01x | 1.33x | 2.43x | 0.29x |
| Net DebtTotal debt minus cash | -$209M | -$1.3B | $35.2B | $40.7B | $9.8B |
| Cash & Equiv.Liquid assets | $219M | $1.4B | $10.3B | $9.2B | $7.3B |
| Total DebtShort + long-term debt | $10M | $96M | $45.5B | $49.9B | $17.2B |
| Interest CoverageEBIT ÷ Interest expense | — | — | 10.70x | 10.34x | 21.32x |
Total Returns (Dividends Reinvested)
KO leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $3,781 for DOCS. Over the past 12 months, KO leads with a +17.2% total return vs DOCS's -64.8%. The 3-year compound annual growth rate (CAGR) favors KO at 13.7% vs DOCS's -15.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -53.7% | -27.3% | +20.3% | +3.5% | -34.2% |
| 1-Year ReturnPast 12 months | -64.8% | -43.5% | +17.2% | +13.4% | -37.1% |
| 3-Year ReturnCumulative with dividends | -38.7% | -16.2% | +47.0% | -11.7% | -20.4% |
| 5-Year ReturnCumulative with dividends | -62.2% | -47.5% | +65.6% | +14.3% | -31.0% |
| 10-Year ReturnCumulative with dividends | -62.2% | +367.2% | +121.1% | +82.3% | +108.7% |
| CAGR (3Y)Annualised 3-year return | -15.0% | -5.7% | +13.7% | -4.1% | -7.3% |
Risk & Volatility
KO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than DOCS's 0.75 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs DOCS's 26.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.75x | 0.69x | -0.20x | -0.11x | 0.64x |
| 52-Week HighHighest price in past year | $76.51 | $310.50 | $84.04 | $171.48 | $276.80 |
| 52-Week LowLowest price in past year | $17.16 | $148.05 | $65.35 | $127.60 | $161.40 |
| % of 52W HighCurrent price vs 52-week peak | +26.2% | +51.4% | +98.3% | +84.1% | +59.9% |
| RSI (14)Momentum oscillator 0–100 | 40.7 | 43.8 | 60.6 | 41.6 | 38.9 |
| Avg Volume (50D)Average daily shares traded | 3.9M | 2.3M | 12.7M | 6.0M | 12.5M |
Analyst Outlook
Evenly matched — KO and PEP each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: DOCS as "Hold", VEEV as "Buy", KO as "Buy", PEP as "Hold", CRM as "Buy". Consensus price targets imply 60.2% upside for CRM (target: $266) vs 4.2% for KO (target: $86). For income investors, PEP offers the higher dividend yield at 3.86% vs CRM's 1.00%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $29.47 | $235.38 | $86.13 | $167.88 | $265.75 |
| # AnalystsCovering analysts | 23 | 43 | 48 | 45 | 97 |
| Dividend YieldAnnual dividend ÷ price | — | — | +2.5% | +3.9% | +1.0% |
| Dividend StreakConsecutive years of raises | — | 0 | 56 | 54 | 2 |
| Dividend / ShareAnnual DPS | — | — | $2.04 | $5.57 | $1.66 |
| Buyback YieldShare repurchases ÷ mkt cap | +11.5% | +0.7% | +0.2% | +0.5% | +9.3% |
DOCS leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KO leads in 2 (Total Returns, Risk & Volatility). 2 tied.
DOCS vs VEEV vs KO vs PEP vs CRM: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is DOCS or VEEV or KO or PEP or CRM a better buy right now?
For growth investors, Veeva Systems Inc.
(VEEV) is the stronger pick with 16. 3% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). Doximity, Inc. (DOCS) offers the better valuation at 20. 4x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate Veeva Systems Inc. (VEEV) a "Buy" — based on 43 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — DOCS or VEEV or KO or PEP or CRM?
On trailing P/E, Doximity, Inc.
(DOCS) is the cheapest at 20. 4x versus Veeva Systems Inc. at 29. 3x. On forward P/E, Doximity, Inc. is actually cheaper at 14. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 27x versus PepsiCo, Inc. 's 5. 11x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — DOCS or VEEV or KO or PEP or CRM?
Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.
6%, compared to -62. 2% for Doximity, Inc. (DOCS). Over 10 years, the gap is even starker: VEEV returned +367. 2% versus DOCS's -62. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — DOCS or VEEV or KO or PEP or CRM?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
20β versus Doximity, Inc. 's 0. 75β — meaning DOCS is approximately -472% more volatile than KO relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 2% for PepsiCo, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — DOCS or VEEV or KO or PEP or CRM?
By revenue growth (latest reported year), Veeva Systems Inc.
(VEEV) is pulling ahead at 16. 3% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: Veeva Systems Inc. grew EPS 25. 9% year-over-year, compared to -13. 7% for PepsiCo, Inc.. Over a 3-year CAGR, DOCS leads at 15. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — DOCS or VEEV or KO or PEP or CRM?
Doximity, Inc.
(DOCS) is the more profitable company, earning 30. 4% net margin versus 8. 8% for PepsiCo, Inc. — meaning it keeps 30. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 33. 3% versus 12. 2% for PEP. At the gross margin level — before operating expenses — DOCS leads at 89. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is DOCS or VEEV or KO or PEP or CRM more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 27x versus PepsiCo, Inc. 's 5. 11x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Doximity, Inc. (DOCS) trades at 14. 0x forward P/E versus 25. 3x for The Coca-Cola Company — 11. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CRM: 60. 2% to $265. 75.
08Which pays a better dividend — DOCS or VEEV or KO or PEP or CRM?
In this comparison, PEP (3.
9% yield), KO (2. 5% yield), CRM (1. 0% yield) pay a dividend. DOCS, VEEV do not pay a meaningful dividend and should not be held primarily for income.
09Is DOCS or VEEV or KO or PEP or CRM better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
20), 2. 5% yield, +121. 1% 10Y return). Both have compounded well over 10 years (KO: +121. 1%, DOCS: -62. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between DOCS and VEEV and KO and PEP and CRM?
These companies operate in different sectors (DOCS (Healthcare) and VEEV (Healthcare) and KO (Consumer Defensive) and PEP (Consumer Defensive) and CRM (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: DOCS is a small-cap quality compounder stock; VEEV is a mid-cap high-growth stock; KO is a large-cap quality compounder stock; PEP is a mid-cap income-oriented stock; CRM is a mid-cap quality compounder stock. KO, PEP, CRM pay a dividend while DOCS, VEEV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.